文献速递免疫规划传染病防控与疫情报告

空前疫情期间重组埃博拉疫苗的临床开发

Clinical development of a recombinant Ebola vaccine in the midst of an unprecedented epidemic.
PubMed 文献 · Vaccine · 2017-06-21

2014-2016年埃博拉疫情造成超过28000例病例和11000例死亡。默克公司与NewLink Genetics等公私合作伙伴并行开展了8项I期和4项II/III期临床试验,约17000名受试者参与,评估V920(rVSVΔG-ZEBOV-GP)的安全性、免疫原性和/或有效性。免疫原性数据显示接种后14天ELISA一般可检出抗GP抗体,至28天血清转换率高达100%;WHO在几内亚开展的环状疫苗接种试验结果提示单剂接种后10天内疫苗有效性稳健。

要点

  • V920为重组水疱性口炎病毒疫苗,VSV-G包膜糖蛋白被扎伊尔埃博拉病毒GP完全替换。
  • 接种后14天ELISA一般可检出抗GP抗体,28天血清转换率高达100%。
  • WHO在几内亚的环状疫苗接种试验提示单剂后10天内疫苗有效性稳健。

核心结论

  • V920疫苗在疫情期间通过公私合作并行开展8项I期和4项II/III期临床试验,约17000名受试者参与,评估其安全性、免疫原性和/或有效性。
  • 免疫原性数据表明接种后14天ELISA一般可检出抗GP抗体,28天血清转换率高达100%。
  • WHO及其伙伴在几内亚开展的环状疫苗接种试验结果提示单剂接种后10天内疫苗有效性稳健。
  • 该疫苗在健康非妊娠成人中一般耐受良好。

研究设计与样本

  • 8项I期和4项II/III期临床试验并行开展,约17000名受试者参与,评估V920的安全性、免疫原性和/或有效性。
  • V920为重组水疱性口炎病毒(rVSV),其VSV-G包膜糖蛋白被扎伊尔埃博拉病毒GP完全替换(rVSVΔG-ZEBOV-GP)。
  • WHO及其伙伴在几内亚开展了环状疫苗接种试验。

主要发现

  • 免疫原性数据表明抗GP抗体一般可在接种后14天通过ELISA检出,至接种后28天观察到高达100%的血清转换率。
  • WHO及其伙伴在几内亚开展的环状疫苗接种试验结果提示单剂接种后10天内疫苗有效性稳健。
  • 疫苗在健康非妊娠成人中一般耐受良好。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The 2014-2016 Ebola outbreak caused over 28,000 cases and 11,000 deaths. Merck & Co. Inc., Kenilworth, NJ USA and NewLink Genetics are working with private and public partners to develop and license an Ebola vaccine that was evaluated extensively during the outbreak. The vaccine referred to as V920 is a recombinant vesicular stomatitis virus (rVSV) in which the VSV-G envelope glycoprotein (GP) is completely replaced by the Zaire ebolavirus GP (rVSVΔG-ZEBOV-GP). Eight Phase I and four Phase II/III clinical trials enrolling approximately 17,000 subjects were conducted in parallel to the outbreak to assess the safety, immunogenicity, and/or efficacy of V920. Immunogenicity data demonstrate that anti-GP antibodies are generally detectable by ELISA by 14days postvaccination with up to 100% seroconversion observed by 28days post dose. In addition, the results of a ring vaccination trial conducted by the WHO and their partners in Guinea suggest robust vaccine efficacy within 10days of receipt of a single dose of vaccine. The vaccine is generally well-tolerated when administered to healthy, non-pregnant adults. The development of this vaccine candidate in the context of this unprecedented epidemic has involved the close cooperation of large number of international partners and highlights what we as a public health community can accomplish when working together towards a common goal. Study identification: V920-001 to V920-012. CLINICALTRIALS.GOV identifiers: NCT02269423; NCT02280408; NCT02374385; NCT02314923; NCT02287480; NCT02283099; NCT02296983; NCT02344407; NCT02378753; NCT02503202.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Coller BG, Blue J, Das R, et al. Clinical development of a recombinant Ebola vaccine in the midst of an unprecedented epidemic. Vaccine. 2017. PMID: 28647166. doi:10.1016/j.vaccine.2017.05.097

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。